FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114156781> ?p ?o ?g. }

• W2114156781 endingPage "674" @default.
• W2114156781 startingPage "663" @default.
• W2114156781 abstract "A concurrent multicenter, randomized Phase II trial employing a recombinant poxviral vaccine provided evidence of enhanced median overall survival (OS) (p = 0.0061) in patients with metastatic castrate-resistant prostate cancer (mCRPC). The study reported here employed the identical vaccine in mCRPC to investigate the influence of GM-CSF with vaccine, and the influence of immunologic and prognostic factors on median OS. Thirty-two patients were vaccinated once with recombinant vaccinia containing the transgenes for prostate-specific antigen (PSA) and three costimulatory molecules. Patients received boosters with recombinant fowlpox containing the same four transgenes. Twelve of 32 patients showed declines in serum PSA post-vaccination and 2/12 showed decreases in index lesions. Median OS was 26.6 months (predicted median OS by the Halabi nomogram was 17.4 months). Patients with greater PSA-specific T-cell responses showed a trend (p = 0.055) toward enhanced survival. There was no difference in T-cell responses or survival in cohorts of patients receiving GM-CSF versus no GM-CSF. Patients with a Halabi predicted survival of <18 months (median predicted 12.3 months) had an actual median OS of 14.6 months, while those with a Halabi predicted survival of > or =18 months (median predicted survival 20.9 months) will meet or exceed 37.3 months, with 12/15 patients living longer than predicted (p = 0.035). Treg suppressive function was shown to decrease following vaccine in patients surviving longer than predicted, and increase in patients surviving less than predicted. This hypothesis-generating study provides evidence that patients with more indolent mCRPC (Halabi predicted survival > or =18 months) may best benefit from vaccine therapy." @default.
• W2114156781 created "2016-06-24" @default.
• W2114156781 creator A5002626470 @default.
• W2114156781 creator A5003174995 @default.
• W2114156781 creator A5004112514 @default.
• W2114156781 creator A5013204681 @default.
• W2114156781 creator A5016328953 @default.
• W2114156781 creator A5018956979 @default.
• W2114156781 creator A5027165899 @default.
• W2114156781 creator A5027334479 @default.
• W2114156781 creator A5044239219 @default.
• W2114156781 creator A5044285326 @default.
• W2114156781 creator A5053535513 @default.
• W2114156781 creator A5055870934 @default.
• W2114156781 creator A5059931764 @default.
• W2114156781 creator A5070669850 @default.
• W2114156781 creator A5073536820 @default.
• W2114156781 creator A5074373285 @default.
• W2114156781 creator A5076389889 @default.
• W2114156781 creator A5080417120 @default.
• W2114156781 creator A5082062582 @default.
• W2114156781 creator A5091525474 @default.
• W2114156781 date "2009-11-05" @default.
• W2114156781 modified "2023-10-09" @default.
• W2114156781 title "Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer" @default.
• W2114156781 cites W2088692565 @default.
• W2114156781 cites W2098574945 @default.
• W2114156781 cites W2099232673 @default.
• W2114156781 cites W2101995865 @default.
• W2114156781 cites W2103090668 @default.
• W2114156781 cites W2117280704 @default.
• W2114156781 cites W2120292596 @default.
• W2114156781 cites W2127283640 @default.
• W2114156781 cites W2130227816 @default.
• W2114156781 cites W2136675736 @default.
• W2114156781 cites W2142302700 @default.
• W2114156781 cites W2142371815 @default.
• W2114156781 cites W2146934263 @default.
• W2114156781 cites W2149467956 @default.
• W2114156781 cites W2153140330 @default.
• W2114156781 cites W2155679349 @default.
• W2114156781 cites W2162138091 @default.
• W2114156781 cites W2162338227 @default.
• W2114156781 cites W2167869791 @default.
• W2114156781 cites W2286739392 @default.
• W2114156781 cites W2537394222 @default.
• W2114156781 cites W2793920357 @default.
• W2114156781 cites W4250744861 @default.
• W2114156781 doi "https://doi.org/10.1007/s00262-009-0782-8" @default.
• W2114156781 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2832083" @default.
• W2114156781 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19890632" @default.
• W2114156781 hasPublicationYear "2009" @default.
• W2114156781 type Work @default.
• W2114156781 sameAs 2114156781 @default.
• W2114156781 citedByCount "269" @default.
• W2114156781 countsByYear W21141567812012 @default.
• W2114156781 countsByYear W21141567812013 @default.
• W2114156781 countsByYear W21141567812014 @default.
• W2114156781 countsByYear W21141567812015 @default.
• W2114156781 countsByYear W21141567812016 @default.
• W2114156781 countsByYear W21141567812017 @default.
• W2114156781 countsByYear W21141567812018 @default.
• W2114156781 countsByYear W21141567812019 @default.
• W2114156781 countsByYear W21141567812020 @default.
• W2114156781 countsByYear W21141567812021 @default.
• W2114156781 countsByYear W21141567812022 @default.
• W2114156781 countsByYear W21141567812023 @default.
• W2114156781 crossrefType "journal-article" @default.
• W2114156781 hasAuthorship W2114156781A5002626470 @default.
• W2114156781 hasAuthorship W2114156781A5003174995 @default.
• W2114156781 hasAuthorship W2114156781A5004112514 @default.
• W2114156781 hasAuthorship W2114156781A5013204681 @default.
• W2114156781 hasAuthorship W2114156781A5016328953 @default.
• W2114156781 hasAuthorship W2114156781A5018956979 @default.
• W2114156781 hasAuthorship W2114156781A5027165899 @default.
• W2114156781 hasAuthorship W2114156781A5027334479 @default.
• W2114156781 hasAuthorship W2114156781A5044239219 @default.
• W2114156781 hasAuthorship W2114156781A5044285326 @default.
• W2114156781 hasAuthorship W2114156781A5053535513 @default.
• W2114156781 hasAuthorship W2114156781A5055870934 @default.
• W2114156781 hasAuthorship W2114156781A5059931764 @default.
• W2114156781 hasAuthorship W2114156781A5070669850 @default.
• W2114156781 hasAuthorship W2114156781A5073536820 @default.
• W2114156781 hasAuthorship W2114156781A5074373285 @default.
• W2114156781 hasAuthorship W2114156781A5076389889 @default.
• W2114156781 hasAuthorship W2114156781A5080417120 @default.
• W2114156781 hasAuthorship W2114156781A5082062582 @default.
• W2114156781 hasAuthorship W2114156781A5091525474 @default.
• W2114156781 hasBestOaLocation W21141567812 @default.
• W2114156781 hasConcept C121608353 @default.
• W2114156781 hasConcept C126322002 @default.
• W2114156781 hasConcept C143998085 @default.
• W2114156781 hasConcept C147483822 @default.
• W2114156781 hasConcept C203014093 @default.
• W2114156781 hasConcept C22070199 @default.
• W2114156781 hasConcept C2777701055 @default.
• W2114156781 hasConcept C2780192828 @default.
• W2114156781 hasConcept C71924100 @default.

• next